<DOC>
	<DOCNO>NCT02421627</DOCNO>
	<brief_summary>To observe safety efficacy moxibustion diarrhea-predominant irritable bowel syndrome evaluation Magnetic Resonance Imaging ( MRI ) .</brief_summary>
	<brief_title>Moxibustion Diarrhea-predominant Irritable Bowel Syndrome</brief_title>
	<detailed_description>1 . A randomized control trial 2 . Moxibustion treatment , placebo control 3 . To observe safety efficacy moxibustion treatment versus placebo control 4 . Evaluation structural MRI rest state-functional MRI</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>1 . Diarrheapredominant IBS patient meet Rome III diagnostic criterion ; 2 . Age 1865 year old , male female ; 3 . Volunteered trial , sign inform consent 1 . Intestinal organic disease ; 2 . Constipationpredominant IBS ; 3 . Alternating diarrhea constipation IBS ; 4 . Unstructured IBS ; 5 . At time , application smecta , dicetel , cisapride traditional Chinese medicine ; 6 . Combined liver , kidney , heart mental disease patient ; 7 . Under age 18 age 65 patient ; 8 . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>moxibustion</keyword>
	<keyword>irritable bowel syndrome</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
</DOC>